Mirobact (Mupirocin)

Mupirocin, the active ingredient in Mirobact, is an antibiotic presented as a topical formulation for skin use. It treats bacterial skin infections such as impetigo, infected eczema and secondary infections, and is applied directly to the affected area.

GNH USA supplies Mirobact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Mirobact is manufactured under EU GMP guidelines and exported to multiple regions under controlled logistics.

Mupirocin is a topical antibacterial agent used to manage common bacterial skin conditions.

Impetigo: eradicates Staphylococcus aureus and Streptococcus pyogenes, reducing lesions and preventing spread. Secondary bacterial infections of the skin: eliminates pathogenic bacteria, promoting healing of compromised skin. Infected eczema: controls bacterial overgrowth, decreasing inflammation and facilitating recovery.

Topical mupirocin may cause local skin reactions and, rarely, systemic adverse events.

Common Side Effects: - Burning sensation at the application site - Itching - Redness - Dryness of the treated skin

Serious or Rare Side Effects: - Allergic contact dermatitis - Stevens‑Johnson syndrome - Neutropenia (rare systemic absorption) - Anaphylaxis

When using Mirobact, follow these safety measures.

Apply only to affected area: limit use to small surface areas to avoid systemic absorption. Avoid use on eyes, ears or mucous membranes: the product is not intended for these sites. Do not cover with occlusive dressings unless directed by a clinician. Use with caution in patients with known hypersensitivity to mupirocin. Store at room temperature: keep in the original pack, protect from moisture.

Mirobact may interact with other medicines; consider the following.

Major Interactions (Avoid): - Use with other topical antibacterial agents – may increase bacterial resistance. - Concurrent systemic antibiotics targeting the same organisms – may diminish mupirocin’s local effect.

Moderate Interactions (Monitor Closely): - Topical corticosteroids – may reduce antibacterial activity. - Occlusive dressings – can enhance percutaneous absorption. - Antifungal creams – may alter skin flora and affect treatment outcome.